

Statement

*The status of payment of subsidy on fertilizers and pendency as on
31.12.2018*

(₹ in crores)

Scheme	BE	Expenditure as on 31.12.2018	Balance Funds Available	Pendency as on 31.12.2018
Indigenous P&K	15,820.35	13642.51	2,177.84	3,675.53
Imported P&K	9,260.00	8776.10	483.90	5,963.75
Indigenous Urea	34,989.50	29067.12	5,922.38	11,293.26
Imported Urea	13,360.00	8890.92	4,469.08	2,341.16
City Compost	10.00	7.14	2.86	9.96
TOTAL	73,439.85	60,383.79	13,056.06	23,283.66

Measures to ensure availability of quality medicines at affordable price

2605. DR. L. HANUMANTHAIHAH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether Government is taking measures to ensure that quality medicines are available at affordable prices for all, particularly the poor and disadvantaged in the country, if so, the details thereof;

(b) whether Government has opened sufficient number of Jan Aushadi Kendras in all the hospitals;

(c) if so, the number of outlets of Jan Aushadi Medical Stores opened during the last three years, State-wise and district-wise; and

(d) whether Government has received any complaints regarding Jan Aushadhi Kendras and its unavailability at so many places?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI MANSUKH MANDAVIYA): (a) Yes Sir. In order to make available quality generic medicines at affordable prices to all, 'Pradhan Mantri Bhartiya Janaushadhi Pariyojana' (PMBJP) was launched by Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. Under this scheme, dedicated outlets known as PMBJP Kendras are opened. Through these outlets, good quality unbranded generic medicines are sold at very affordable prices. As on 31.12.2018, 4677 PMBJP Kendras are functional across the country.

(b) Yes Sir. As on 31.12.2018, 737 PMBJP Kendras are functional in Government Hospitals of the country.

(c) A State/UT-wise list of 547 PMBJP Kendras opened in Government Hospitals during the last three years is given in the Statement.

(d) Yes Sir.

Statement

State/UT-wise list of 547 PMBJP Kendras opened in Government Hospitals during the last three years is given in the Statement

Sl. No.	Name of the State/UT	Number of PMBJP Kendras opened		
		2016-17	2017-18	2018-19 (as on 31.12.2018)
1	2	3	4	5
1.	Andaman and Nicobar Islands	0	0	1
2.	Andhra Pradesh	8	7	3
3.	Arunachal Pradesh	13	8	0
4.	Assam	1	1	1
5.	Bihar	0	14	4
6.	Chandigarh	1	0	0
7.	Chhattisgarh	28	24	7
8.	Delhi	1	0	0
9.	Goa	0	0	5
10.	Haryana	0	0	5
11.	Himachal Pradesh	1	2	3
12.	Jammu and Kashmir	2	1	2
13.	Jharkhand	0	3	0
14.	Karnataka	14	97	23
15.	Kerala	0	3	1
16.	Madhya Pradesh	1	0	2
17.	Manipur	0	26	0
18.	Mizoram	1	1	0
19.	Nagaland	11	0	3

1	2	3	4	5
20.	Odisha	0	0	0
21.	Punjab	0	4	2
22.	Rajasthan	1	15	11
23.	Tamil Nadu	0	0	1
24.	Telangana	0	1	0
25.	Tripura	1	12	1
26.	Uttar Pradesh	0	0	121
27.	Uttarakhand	2	17	29
TOTAL		86	236	225
GRAND TOTAL		547		

Delay in pricing process of new drugs

2606. SHRI B.K. HARIPRASAD: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that present practice of deciding price for new drugs is causing delay in launch of the new drugs in the market by the manufacturer;

(b) if so, the details thereof and the reason therefor; and

(c) the course of action for expeditious pricing of new drugs as it is the main driver of growth of the industry and provides scope for innovation?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI MANSUKH MANDAVIYA): (a) and (b) No Sir, there is no such inordinate delay in fixing the prices of new drugs. Out of 979 applications received till 30th November, 2018, notifications for fixing the retail prices of 920 applications for new drugs have already been issued. Under the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), all drug manufacturers are under obligation to issue a price list to distributors, State Drug Controllers and the Government. The new drug applications of only those manufacturers/marketers were temporarily put on hold by National Pharmaceutical Pricing Authority (NPPA), who had either not submitted the complete information for Integrated Pharmaceutical Database Management System (IPDMS) or had *prima facie* launched new drugs without prior price approvals. Other cases have been pending because of non-submission of necessary data by the industry.

(c) The Government regularly monitors the number of manufacturers in the market for various formulations and that there is sufficient flow of medicines in the market.